Market Overview

Co-Diagnostics Announces Filing of S-3 Shelf Registration


Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics
company with a unique, proprietary platform for the development of
molecular diagnostic tests, announced today the filing of a shelf
registration statement on Form S-3 with the Securities and Exchange
Commission ("SEC") to sell up to an aggregate amount of $25 million of
its shares, which amount shall be subject to securities regulations.

This announcement follows the Company's most recent Form 10Q filing and
the closure of $2 Million in debt financing announced on Friday, Aug.
10, 2018, and other press releases concerning advancements in the
Company's SNP detection technology and the CE marking of its Logix
Smart™ MTB test.

Dwight Egan, Chief Executive Officer of Co-Diagnostics, commented, "This
Form S-3 shelf registration statement enhances the Company's financial
flexibility in the event appropriate opportunities present themselves.
We are confident that the cost-saving and scientific advantages that our
technology makes available to laboratories and customers alike will not
only facilitate a leap forward in research but increase accessibility of
these life-changing diagnostics worldwide."

A Form S-3 filing (also referred to as a shelf offering or shelf
registration) allows a public company to register securities in a
simpler format than that of an S-1 registration, even if no present
intention exists to sell all securities being registered. The Company
became eligible to file the Form S-3 one year after their initial public
offering in July 2017.

The terms of any securities offered under the registration statement,
and the intended use of the net proceeds resulting therefrom, will be
established at the times of the offerings, if any, and will be described
in prospectus supplements filed with the SEC at the times of the

Although the registration statement relating to these securities has
been filed with the SEC, it has not yet become effective and, at the
present time, Co-Diagnostics does not have any commitments to sell
securities under the shelf registration statement.

These securities may not be sold, nor may offers to buy be accepted,
prior to the time the registration statement becomes effective. This
press release is not an offer to sell or a solicitation of an offer to
buy, nor shall there be any sale of securities in any state or
jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any
such state or jurisdiction.

A copy of the shelf registration statement on Form S-3 and copies of the
prospectus supplements relating to any offerings under the registration
statement, when available, can be obtained by contacting Investor

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics
company that develops, manufactures and markets a new, state-of-the-art
diagnostics technology. The Company's technology is utilized for tests
that are designed using the detection and/or analysis of nucleic acid
molecules (DNA or RNA). The Company also uses its proprietary technology
to design specific tests to locate genetic markers for use in industries
other than infectious disease and license the use of those tests to
specific customers.

Forward-Looking Statements:

This press release contains forward-looking statements.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans," "will"
and similar expressions, or the negative of these words. Such
forward-looking statements are based on facts and conditions as they
exist at the time such statements are made and predictions as to future
facts and conditions.
Forward-looking statements in this release
include statements regarding the (i) use of funding proceeds, (ii)
expansion of product distribution, (iii) acceleration of initiatives in
liquid biopsy and SNP detection, (iv) use of the Company's liquid biopsy
tests by laboratories, (v) capital resources and runway needed to
advance the Company's products and markets, (vi) increased sales in the
near-term, (vii) flexibility in managing the Company's balance sheet,
(viii) anticipation of business expansion, and (ix) benefits in research
and worldwide accessibility of the CoPrimer technology and its
cost-saving and scientific advantages. Forward-looking statements are
subject to inherent uncertainties, risks and changes in circumstances.

Actual results may differ materially from those contemplated or
anticipated by such forward-looking statements. Readers of this press
release are cautioned not to place undue reliance on any forward-looking
statements. The Company does not undertake any obligation to update any
forward-looking statement relating to matters discussed in this press
release, except as may be required by applicable securities laws.

View Comments and Join the Discussion!